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Hancornia speciosaGomes is a fruit tree, commonly known as the mangaba tree, which is widespread throughout Brazil. The leaves
of this plant are used in traditional medicine for medicinal purposes. Thus, the objective of this study was to perform a
physicochemical characterization, identify the lipophilic antioxidants and fatty acids, and determine the microbiological quality
and safety of H. speciosa leaves. In addition, the antioxidant, antimutagenic, and inhibitory activities of the ethanolic extract of
H. speciosa leaves (EEHS) against enzymes related to neurodegenerative diseases, inflammation, obesity, and diabetes were
investigated. Furthermore, this study aimed at assessing the in vivo effects of the EEHS on the glycemia of normoglycemic and
diabetic Wistar rats. Physicochemical characterization was performed by colorimetry and gas-liquid chromatography with flame
ionization detection (GC-FID). The total number of colonies of aerobic mesophiles, molds, and yeasts was determined. The total
coliforms and Escherichia coli were counted using the SimPlates kit, and sulphite-reducing Clostridium spores were quantified
using the sulphite-polymyxin-sulfadiazine agar method. Salmonella spp. were detected using the 1-2 Test. The antioxidant activity
of the EEHS was measured by its inhibition of 2,2′-azobis(2-amidinopropane) dihydrochloride- (AAPH-) induced oxidative
hemolysis of human erythrocytes. The antimutagenic activity was determined using the Ames test. The acetylcholinesterase,
butyrylcholinesterase, tyrosinase, hyaluronidase, lipase, α-amylase, and α-glycosidase enzyme-inhibiting activities were assessed
and compared with commercial controls. The in vivo effects of the EEHS were assessed using the oral glucose tolerance test in
normoglycemic Wistar rats and measuring the blood glucose levels in diabetic rats. The results demonstrated physical-chemical
parameters of microbiological quality and safety in the leaves of H. speciosa, as well as antioxidant and antimutagenic activities
and inhibition of enzymes related to neurodegenerative diseases, inflammation, obesity, and diabetes. In in vivo assays, it was
shown that the normoglycemic rats challenged with glucose overload show significantly decreased blood glucose levels when
treated with the EEHS. Taken together, the results ensure the microbiological quality and safety as well as showing the contents of
carotenoids and polyunsaturated fatty acids of H. speciosa leaves. Additionally, the antioxidant, antimutagenic, anti-inflammatory,
anti-Alzheimer’s disease, anti-Parkinson’s disease, antiobesity, and antihyperglycemic activities of the EEHS were demonstrated.
1. Introduction
In different cultures worldwide, medicinal plants are used for
therapeutic purposes. Although the microbiological quality
of these materials is still rarely discussed, it is essential
to achieve the expected pharmacological outcomes. Plant
materials for medicinal purposes need to have acceptable
microbial contamination levels and no deterioration or
Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2018, Article ID 2976985, 17 pages
https://doi.org/10.1155/2018/2976985
pathogenic microorganisms [1]. These basic criteria must be
assessed and followed to obtain plant samples with quality,
safety, and therapeutic efficacy [2, 3].
In Brazil, several plants are used in traditional medicine,
including Hancornia speciosa Gomes (H. speciosa). This fruit
tree, commonly known as the mangaba tree, belongs to
the Apocynaceae family, and its leaves are sold as tea
[4]. This species is native to Brazil and is found in the
Amazonia, Caatinga, and Atlantic forests as well as the
Cerrado (Brazilian savannah) biomes.
The antioxidant, antimicrobial, cytotoxic [4], anti-
inflammatory [5, 6], wound-healing [6], vasodilation
[7, 8], antihypertensive [9, 10], antidiabetic [11], and
acetylcholinesterase-inhibiting [12] activities of H. speciosa
leaves have been described. Previously reported phytochem-
ical studies with H. speciosa leaf extracts showed a complex
chemical composition. The identified chemical constitu-
ents that were related to the biological activities include
L-(+)-bornesitol, quinic acid, chlorogenic acid, and
kaempferol, quercetin, isoquercetin, rutin, and catechin
flavonoids [4, 5, 11, 13, 14]. Recently, Bastos et al. [15]
identified other phenolic compounds, including caffeic
acid, protocatechuic acid isomers, epicatechin, quercetin
isomers, type-B and type-C procyanidins, coumaroylquinic
acid isomers, phlorizin, phloretin, eriodictyol, luteolin, and
apigenin. Natural extracts and phenolic derivatives with
pharmacological potential may serve as a safe and cost-
effective treatment strategy as an alternative to synthetic
drugs [16–19].
Plants are sources of biologically active compounds that
are used by approximately 80% of the world’s population,
either as tea or as pharmaceutical drugs [20]. Furthermore,
natural products or derivatives play a key role in the process
of the development and discovery of new compounds or
drugs [21]. Over the past three decades, drugs developed
from natural products have been prominent because among
the drugs available for treatment, 50% for Alzheimer’s dis-
ease, 8% for Parkinson’s disease, 27% for inflammation,
16% for obesity, and 57% for diabetes are derived directly
or indirectly from natural products [21].
Thus, the objective of this study was to perform a
physicochemical characterization, identify the lipophilic
antioxidants and fatty acids, and determine the microbio-
logical quality and safety of H. speciosa leaves. In addition,
the antioxidant, antimutagenic, and inhibitory activities
against enzymes related to neurodegenerative diseases,
inflammation, obesity, and diabetes of the ethanolic extract
of H. speciosa leaves (EEHS) were investigated. Further-
more, this study aimed to assess the in vivo effects of the
EEHS on the glycemia of normoglycemic and diabetic
Wistar rats.
2. Materials and Methods
2.1. Plant Material and Ethanol Extract Preparation. H. spe-
ciosa leaves were collected after identifying the plant and
receiving permission from the Brazilian Biodiversity Autho-
rization and Information System (Sistema de Autorização e
Informação em Biodiversidade, SISBIO; number 54470-1).
The plant material was collected in Dourados, Mato Grosso
do Sul State (21° 59′ 41′′ south and 55° 19′ 24′′ west), Brazil,
dried in a convection oven at a temperature of 45± 5°C, and
ground in a Wiley knife mill. A voucher specimen was
deposited in the herbarium of the Federal University of
Grande Dourados, Mato Grosso do Sul State, Brazil, under
record number 4774. The extract was prepared by macerat-
ing the plant material in 96% ethanol (1 : 10, w/v). The
mixture was kept at room temperature for 14 days. Subse-
quently, the extract was filtered, concentrated in a rotary
evaporator under vacuum (Gehaka, São Paulo, SP, Brazil),
and freeze-dried. The EEHS had a final yield of 28% and
was stored at −20°C in the dark. The flavonoids rutin,
catechin, and isoquercetin, previously identified in the
EEHS by high-performance liquid chromatography with
diode-array detection-tandem mass spectrometry (HPLC-
DAD-MS/MS) [4] and used in this study, were purchased
from Sigma-Aldrich.
2.2. Physicochemical Analysis
2.2.1. Ash Content. The method used to determine the ash
content of H. speciosa leaves consisted of desiccating
250mg of leaf samples. The test was performed in triplicate,
and the result is expressed as g/100 g of sample [22].
2.2.2. Total Protein Content. The protein content was deter-
mined using the Kjeldahl method (230-Kjeltec Analyzer,
Foss Tecator, Höganäs, Sweden), as described by Nogueira
et al. [23]. The protein concentration was determined by
multiplying the value of the total nitrogen by the factor 5.75
(P protein =N nitrogen × 5 75). The test was performed in
triplicate, and the result is expressed as g/100 g of sample.
2.2.3. Total Lipids. The crude fat was determined by gravim-
etry after extraction with petroleum ether using an automatic
Soxtec device (FOSS, Soxtec™ 2050, Höganäs, Sweden) [22].
The test was performed in triplicate, and the result is
expressed as g/100 g of sample.
2.2.4. Carbohydrates and Energy. The carbohydrate content
of the sample was calculated by the following difference:
100− (g proteins + g lipids + g ash). The total energy was
calculated using the following equation: energy (kcal) = 4×
(g proteins + g carbohydrates) + 9× (g lipids). The tests were
performed in triplicate, and the results are expressed as
g/100 g of sample for carbohydrates and as kcal/100 g of
sample for energy.
2.2.5. Lipophilic Antioxidants. The lipophilic antioxidants
β-carotene, lycopene, and chlorophyll a and b were deter-
mined using dried and powdered leaf samples (150mg)
vigorously stirred in 10mL of an acetone-hexane mixture
(4 : 6, v/v) for 1min and filtered through a Whatman®
Grade 4 qualitative filter paper. The absorbance of the
filtrate was measured at 453, 505, 645, and 663nm. The
β-carotene, lycopene, and chlorophyll a and b contents
were calculated using the following equations: β-carotene
(mg/100mL)= 0.216×A663–1.220×A645− 0.304×A505 +
0.452×A453; lycopene (mg/100mL) = −0.0458×A663 +
2 Oxidative Medicine and Cellular Longevity
0.204×A645 + 0.304×A505− 0.0452×A453; chlorophyll
a (mg/100mL)= 0.99×A663− 0.0989×A645; and chloro-
phyll b (mg/100mL)=−0.328×A663+ 1.77×A645. The
results are expressed as mg/100 g of sample [23].
2.2.6. Fatty Acid Composition. The total lipids extracted from
dried and powdered leaf samples of H. speciosa were
subjected to transesterification with 2.5mL of methanol,
1.25mL of sulfuric acid, and 1.25mL of toluene (2 : 1 : 1 ratio
(v/v)) for at least 12 h in a water bath at 50°C and 160 rpm.
After this period, 3mL of deionized water and 3mL of diethyl
ether were added. The mixture was stirred and left to stand
until phase separation. The upper phase of fatty acid methyl
esters (FAMEs) was recovered using an anhydrous sodium
sulfate microcolumn and transferred to a glass vial using a
0.2μm Millipore nylon filter before injection into the device
[24]. The sample FAMEs were determined by gas chroma-
tography with flame-ionization detection (GC-FID) in a
capillary column of the DANI GC 1000 chromatograph
(Izasa, Barcelona, Spain), which is equipped with a split/
splitless injector, a flame ionization detector, and a
Macherey-Nagel column (30m× 0.32mm ID× 0.25μm df).
The initial temperature of the column was 50°C for 2min,
followed by a 30°C/min increase until 125°C, a 5°C/min
increase until 160°C, a 20°C/min increase to 180°C, and a
3°C/min increase until 200°C. Lastly, the temperature was
increased at 20°C/min until the limit of 220°C, where it was
held for 15min. The total analysis time was 35.16min. The
gas (hydrogen) was maintained at a flow rate of 4.0mL/min
(0.61 bar) at 50°C. The injection (1 : 40) was performed at
220°C. For each analysis, 1μL of sample was injected into
the GC. The fatty acids were identified by comparing the
retention times of the peaks of standard FAMEs (Supelco
37 Component FAMEmix) with those of the sample FAMEs.
The results were processed using CSW 1.7 software (DataA-
pex 1.7, Prague, Czech Republic), and the data are expressed
as the relative percentage of each fatty acid.
2.3. Microbiological Tests. The following parameters were
assessed: mesophilic microorganisms, molds, yeasts, total
coliforms, Escherichia coli, sulphite-reducing Clostridium
spores, and Salmonella spp. All microbiological tests were
performed in triplicate.
2.3.1. Sample Preparation. The samples were prepared as
previously described by Gomes et al. [25]. For this, 25 g
of dried and powdered leaves of H. speciosa were
aseptically weighed and homogenized using Stomacher
Lab-Blender (Seward type 400, London, UK) for 3 minutes
with 225mL of sterile peptone physiological saline solution
(0.1% peptone +0.85% NaCl in sterile deionized water,
pH=7.0± 0.05). After 24 hours, serial dilutions were
prepared from this homogenate (initial dilution) with the
same sterile diluents that were used for quantification of
the different microorganisms.
2.3.2. Total Mesophilic Count. The mesophilic aerobic micro-
organisms were counted by adding 1mL of each dilution of
the leaves of H. speciosa to plate count agar (PCA) media
(Himedia, Mumbai, India), in accordance with Portuguese
law 3788 [26]. Microbial counts are expressed as colony-
forming units per gram (cfu/g) of sample.
2.3.3. Mold and Yeast Counts.Molds and yeasts were counted
by adding 1mL of the dilution of the leaves of H. speciosa
in yeast peptone dextrose agar (PDA) media (Himedia,
Mumbai, India) incubated at 25°C for 5 days [27]. Micro-
bial counts are expressed as colony-forming units per
gram (cfu/g) of sample.
2.3.4. Staphylococcus aureus Count. Staphylococcus aureus
(S. aureus) was quantified according to protocol NP
4400-1 [28]. Serial dilutions of the leaves of H. speciosa
were inoculated in Baird-Parker broth with egg yolk tellu-
rite emulsion (Himedia) for 24 h (37°C). Subsequently,
three to five typical colonies were selected to control for
the presence of coagulase and catalase. Microbial counts
are expressed as cfu/g of sample.
2.3.5. Total Coliform and Escherichia coli Counts. The total
coliform and Escherichia coli (E. coli) were counted using
the SimPlate method [29], according to the manufacturer’s
instructions and procedures.
For this, 1mL aliquots of the serial dilutions of the leaves
of H. speciosa were mixed with 9mL of a blue solution
supplied by the manufacturer and dispensed into the center
of the SimPlate device. The SimPlate has undergone slight
rotations to disperse the sample and remove the air bubbles.
Samples were incubated at 37± 1°C for 24 to 48 h. The
positive count of total coliforms was based on the change in
color from blue to pink, and the positive count of E. coli
was based on the change in color and UV fluorescence. Coli-
forms and E. coli were quantified by counting the number of
positive wells, followed by the correlation with the conver-
sion table, and the results are expressed as cfu/g of sample.
2.3.6. Enumeration of Sulphite-Reducing Clostridium Spores.
To the enumeration of sulphite-reducing Clostridium spores,
0.1, 1, 5, and 10mL aliquots of the initial dilution were added
to empty tubes, which were heated to 80°C for 5min and
incubated with iron sulphite agar (ISA) media [30] in anaer-
obic conditions at 37°C for 5 days. The results are determined
based on the enumeration of sulphite-reducing Clostridium
spores in 0.01 g of sample and expressed as cfu/g of sample.
2.3.7. Salmonella spp. Detection. Salmonella spp. were
detected using the immunodiffusion 1-2 test [29]. The test
was performed by adding 100μL of sample (initial dilution)
preenriched in buffered peptone water and 50μL of specific
antibody included in the test kit. To confirm immunoband
formation, the test samples were read after 16 to 20 h of
incubation at 37°C.
2.4. Antioxidant Activity Assessment
2.4.1. Preparation of Human Erythrocyte Suspensions. The
protocol of human peripheral blood collection was
approved by the Research Ethics Committee (Comitê de
Ética em Pesquisa (CEP)) of the University Centre of the
Grande Dourados (Centro Universitário da Grande Dour-
ados), Brazil (process CEP number 123/12). Peripheral
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blood was collected from healthy human donors after they
signed the informed consent form. The samples were
transferred into tubes with sodium citrate as an anticoag-
ulant and centrifuged at 1500 rpm for 10min at 4°C to
separate the hemocomponents. Blood plasma and the thin
layer of leukocytes were removed. The erythrocytes were
washed three times with phosphate-buffered saline (PBS,
pH=7.4) and centrifuged at 1500 rpm for 10min at 4°C
in each washing. Lastly, a 2% hematocrit suspension was
prepared in PBS.
2.4.2. Antihemolytic Activity. The assays were conducted
with an erythrocyte suspension (2%) preincubated at
37°C for 30 minutes with 20μg/mL EEHS or with the
flavonoid rutin, catechin, or isoquercetin individually, sol-
ubilized in dimethyl sulfoxide (DMSO; final concentration
up to 0.08%). After this period, 50mM 2,2′-azobis(2-ami-
dinopropane) dihydrochloride (AAPH) solution was added
to the groups subjected to hemolysis induction. This mix-
ture was incubated at 37°C for 4 h with frequent stirring.
Erythrocytes incubated with PBS, the extract, and flavo-
noids only were used as negative controls. After every
60min of incubation, the samples were centrifuged at
4000 rpm for 10min, and an aliquot was collected from the
supernatant, followed by dilution in PBS. Then, the samples
were read at 545 nm. The percentage of hemolysis was calcu-
lated using the formula A/B × 100, where A represents the
sample absorbance and B represents the total hemolysis
(erythrocytes incubated in distilled water). The assays were
performed in triplicate. Percentage values were set for the
third hour of incubation. The percentage of inhibition of
hemolysis as a function of the sample concentration was also
determined from the concentration-response curve.
2.5. Antimutagenic Activity. The antimutagenic activity was
assessed using the Ames test, with some modifications [31].
Two strains were used for the assay, Salmonella typhimurium
TA98 and TA100, genetically modified with a mutation in the
histidine operator gene, which causes the strains to grow in a
histidine-dependent manner. The activities of the direct muta-
gens sodium azide (SAZ) and 4-nitroquinoline 1-oxide
(4NQO) and the indirect mutagen aflatoxin (AFB1) were
assessed. The rates of inhibition of the mutagenic activity
induced by the EEHS (5–15μg/mL) and flavonoids (0.1–
0.5μg/mL) were calculated using the following equation: rate
of inhibition % = A − B /A × 100, where A is the number
of revertants in the presence of mutagens and B is the
number of revertants in the presence of mutagens and
samples after subtracting the number of spontaneous rever-
tants. Values>80% viable cells were considered nontoxic
compared with the negative control viability. The antimuta-
genic effect was considered moderate when the inhibitory
effect ranged from 25 to 40% and high when it was greater
than 40%. Effects lower than 25% were considered irrelevant
and were disregarded.
2.6. Enzyme-Inhibiting Activity Assessment
2.6.1. Cholinesterase-Inhibiting Activity. The acetylthiocholi-
nesterase- (AChE-) and butyrylthiocholinesterase- (BChE-)
inhibiting activities were assessed based on the spectrophoto-
metric method described by Senol et al. [32] using acetylthio-
choline and butyrylthiocholine as substrates. Aliquots of
50μL of the EEHS or flavonoids (200–700μg/mL) diluted
in EtOH/buffered phosphate (0.1mM, pH=8) were incu-
bated with 25μL acetylcholinesterase (AChE) from Elec-
trophorus electricus (Type-VI, EC 3.1.1.7, Sigma-Aldrich,
USA) and 125μL of 5,5′-dithiobis (2-nitrobenzoic acid)
(0.01M) (DTNB, Sigma-Aldrich, USA) for 15minutes at
25°C. The same procedure was performed to evaluate the
activity of butyrylcholinesterase (BChE) from horse serum
(EC 3.1.1.8, Sigma-Aldrich, USA). Subsequently, the reac-
tions were initiated with the addition of 25μL of the
substrates acetylthiocholine iodide and butyrylthiocholine
chloride (0.075M, Sigma-Aldrich, USA), respectively,
diluted in EtOH/phosphate buffer (0.1mM, pH=8). The
hydrolysis of substrates was monitored by the formation
of the yellow 5-thio-2-nitrobenzoate anion as a result of
the reaction with the 5,5′-dithiobis(2-nitrobenzoic acid)
(0.01M) (DTNB, Sigma-Aldrich, EUA) at 412 nm. All tests
were performed in triplicate. Eserine (0.001–0.01μg/mL)
(Sigma-Aldrich, USA) was used as a reference compound.
The percentages of AChE/BChE enzyme inhibition were
determined comparing the reaction rates of the samples
compared with the blank (ethanol in phosphate buffer
(0.1mM, pH=8)) using the following formula: E − S /
E × 100, where E is the enzymatic activity without test
samples and S is the enzymatic activity with test samples.
The IC50 values were calculated.
2.6.2. Tyrosinase-Inhibiting Activity. The tyrosinase-
inhibiting activity was assessed using the method described
by Orhan and Khan [33], with some modifications. Aliquots
of 25μL of the EEHS or flavonoids (50–1000μg/mL) were
mixed with 40μL of the tyrosinase solution (EC 1.14.1.8.1,
30U mushroom tyrosinase, Sigma-Aldrich, 200U/mL) and
100μL of buffer phosphate solution (pH6.8) in a 96-well
microplate, incubated for 15min at 37°C. Subsequently,
40μL of L-DOPA (3,4-dihydroxy-L-phenylalanine) was
added to the mixture which was incubated for 10min at
37°C. The reading of the absorbance was performed at
492 nm. Kojic acid (2.5–20μg/mL) was used as the refer-
ence compound.
All tests were performed in triplicate. The percentage
of tyrosinase inhibition was calculated using the follow-
ing formula: % inhibition = [(blank absorbance− sample
absorbance)/blank absorbance]× 100. The IC50 values
were calculated.
2.6.3. Hyaluronidase-Inhibiting Activity. The assay was
performed as described by Ling et al. [34], with some
modifications. For this, a mixture of 80U of the enzyme
hyaluronidase in 100μL of 20mM sodium phosphate buffer
and 25μL of EEHS or flavonoids (35μg/mL) dissolved in
25% (v/v) DMSO was incubated for 10min at 37°C. After-
wards, 100μL of hyaluronic acid (0.03% in 300mM sodium
phosphate buffer, pH5.35) was added and incubated for
45min at 37°C. The undigested hyaluronic acid was precipi-
tated with 1mL of acidic albumin solution (0.1% bovine
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albumin in 24mM sodium acetate and 79mM acetic acid at
pH3.75). Posteriorly, the samples were incubated at room
temperature for 10min. The reading of the absorbance was
performed at 600 nm. Absorbance in the absence of enzyme
was used as a reference for maximal inhibition. Epigallocate-
chin (35μg/mL) was used as the reference compound. The
tests were performed in triplicate. The inhibitory activity of
the test sample was calculated using the following formula:
inhibition % = At test sample /Aref reference sample × 100.
2.6.4. α-Amylase-Inhibiting Activity. The α-amylase-inhibiting
activity was assessed as described by Gao et al. [35]. Blue
starch (Sigma-Aldrich; 2.0mg) was used as the substrate in
50mM Tri-HCl buffer at a pH of 6.9 containing 10mM
CaCl2 and boiled for 5min at 100
°C. Then, the starch azure
solution was preincubated for 10min at 37 C. The samples
of the EEHS or flavonoids (20–100μg/mL) were dissolved
in 25% DMSO, and 200μL of porcine pancreatic a-amylase
solution (Sigma-Aldrich, A-6255; 2.0U/mL; 50mM Tri-
HCl buffer containing 10mM CaCl2, pH6.9) was added into
each assay. The reaction was carried out at 37°C for 10min
and stopped by adding 0.5mL of 50% acetic acid. The reac-
tion mixture was then centrifuged at 2000 rpm for 5min at
4°C. The absorbance of the supernatant at 595nm was
measured. Acarbose (20–100μg/mL) was used as the refer-
ence compound. The tests were performed in triplicate. The
α-amylase-inhibiting activity was calculated using the
following formula: %inhibition = Ac+ − Ac− − As − Ab /
Ac+ − Ac− × 100, where Ac+ is the activity in the presence
of 100% enzyme (solvent with enzyme), Ac− is the activity in
the presence of 0% enzyme (solvent without enzyme), As is
the enzyme-inhibiting activity of the test sample (sample
with enzyme), and Ab is the blank (test sample without
enzyme). The IC50 values were calculated.
2.6.5. α-Glucosidase-Inhibiting Activity. The α-glucosidase-
inhibiting activity was assessed according to Mayur et al.
[36], with minor modifications. The reaction mixture
contained 50μL of 0.1M phosphate buffer (pH7.0), 25μL
of 0.5mM 4-nitrophenyl α-D-glucopyranoside, 10μL of the
EEHS or flavonoids (25–85μg/mL), and 25μL of α-glucosi-
dase solution (0.2 unit/mL). The mixture was then incubated
at 37°C for 30min, and the reaction was terminated by
adding 100μL of 0.2M sodium carbonate solution. The
enzymatic hydrolysis of substrate was monitored through
the amount of p-nitrophenol released in the reaction mixture
at 410nm. Individual blanks were prepared for correcting
background absorbance, being the enzymes replaced by
0.1M phosphate buffer (pH7.0). In controls, the plant
extract or flavonoids were replaced by methanol. Acarbose
(25–85μg/mL) was used as a positive control. The inhibi-
tion percentage of α-glucosidase was calculated through
the formula: % inhibition = [1− (sample absorbance/control
absorbance)]× 100. The IC50 values were compared;
analyses were carried out in triplicate.
2.6.6. Lipase-Inhibiting Activity. The porcine pancreatic
lipase (PPL) (type II-inhibiting, Sigma-Aldrich) activity was
assessed using the spectrophotometric method described by
Roh and Jung [37]. EEHS or flavonoids (final concentra-
tions of 2.5–35μg/mL) were preincubated with PPL
(1mg/mL) for 1 h in a potassium phosphate buffer
(0.1mM, pH7.2, 0.1% Tween 80) at 30°C before assaying
the PPL activity. 0.1μL p-nitrofenil Butirato (Sigma-
Aldrich) was then added as a substrate. After incubation
at 30°C for 5min, the amount of p-nitrophenol released
in the reaction was measured at 405nm using a UV-
visible spectrophotometer. The activity of the negative
control (DMSO) was also evaluated with and without an
inhibitor. All tests were performed in triplicate. Orlistat
(0.003–0.01μg/mL) was used as the reference compound.
The PPL-inhibiting activity was calculated using the
following formula: inhibitory activity % = 100 − B − b /
A − a × 100 , where A is the activity without an inhibi-
tor, a is the negative control without an inhibitor, B is
the activity with an inhibitor, and b is the negative con-
trol with an inhibitor. The IC50 values were calculated.
2.7. In Vivo Studies
2.7.1. Animals. All experimental procedures with animals
were submitted to and approved by the Ethics Committee
on Animal Use of the University of Brasília (permission-
UnBDOC number 47926/2010) and conducted in accor-
dance with the norms of the National Council for the Control
of Animal Experimentation (Conselho Nacional de Experi-
mentação Animal (CONCEA)). 120-day-old adult male
Wistar rats were obtained from the animal house of the
School of Biological and Environmental Sciences, Federal
University of Grande Dourados, Mato Grosso do Sul State,
Brazil. The animals were kept in polyethylene boxes at 22
± 2°C and in a controlled light-dark cycle (12/12 h). All
animals were fed ad libitum.
2.7.2. Oral Glucose Tolerance Test in Normoglycemic Wistar
Rats. The oral glucose tolerance test (OGTT) was performed
after 12 hours of fasting in adult 120-day-old male normogly-
cemic Wistar rats. The animals were challenged with glucose
overload by oral gavage (2 g/kg body mass). After 30 minutes,
the vehicle control dimethyl sulfoxide (6% DMSO) and
EEHS (200 and 400mg/kg body mass) treatments were
performed. Rat glycemia was measured at 0, 30, 60, 120,
and 180min after delivering the glucose overload according
to Aragão et al. [38] using the Accu-Chek Active (Roche)
blood glucose meter and disposable strips.
2.7.3. Diabetes Induction. Diabetes was induced in adult
120-day-old male Wistar rats with a single intraperitoneal
injection of alloxan monohydrate (120mg/kg body mass)
dissolved in 0.9% sterile saline, as described by Aragão
et al. [38], with some modifications. Blood glucose levels
were determined 96 h after the induction of diabetes using
a portable Accu-Chek (Abbott) blood glucose meter and
disposable strips. The animals with hyperglycemia (blood
glucose levels higher than 200mg/dL) were separated for
further study.
2.7.4. Glycemic Assessment in Diabetic Wistar Rats. The treat-
ment and glycemic assessment of diabetic male Wistar rats
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were performed according to Aragão et al. [38], with some
modifications. The blood glucose levels of diabetic rats
submitted to acute and chronic treatment (28 days) were
measured during fasting at time zero, and they were subse-
quently administered with the doses of vehicle control 6%
DMSO, EEHS (200mg/kg body mass), and metformin
(120mg/kg body mass). The blood glucose levels of the rats
were measured at times of 0, 30, 60, 120, and 180min using
the Accu-Chek Active (Roche) blood glucose meter and
disposable strips.
2.8. Statistical Analysis. The data are expressed as the
mean± standard error of the mean (SEM) and were ana-
lyzed to assess significant differences between groups. One-
way analysis of variance was used for the total composition
of FAMEs as well as antihemolytic, enzyme-inhibiting, and
antimutagenic activities. Differences were determined using
the multiple comparison Tukey test for the results of the total
composition of FAMEs and antihemolytic activity. Dunnett’s
multiple comparison test was used to assess differences in
enzyme inhibition and antimutagenicity assays. The t-test
was used in the in vivo experiments to assess differences
between groups. All data were obtained using the Software
GraphPad Prism 5. Results were considered significant
when ∗P < 0 05 or †P < 0 05, ∗∗P < 0 01, and ∗∗∗P < 0 001
or ###P < 0 001.
3. Results
3.1. Physicochemical Parameters. Physicochemical parame-
ters, including the mineral (ash), protein, total lipid, and car-
bohydrate contents as well as the energy value of H. speciosa
leaves, are outlined in Table 1.
3.2. Lipophilic Antioxidants. Chlorophyll a and β-carotene
were the predominant antioxidants, with 1.33± 0.03 and
0.55± 0.01mg/100 g of sample, respectively. Conversely, the
concentration of chlorophyll b was 0.42± 0.02mg/100 g,
and the concentration of lycopene was 0.070± 0.01mg/100 g.
3.3. Profile of Fatty Acid Methyl Esters. After total lipid
extraction from H. speciosa leaves, the profiles of FAMEs
were analyzed by gas chromatography (Figure 1(a)). The α-
linolenic acid (C18:3n3) was the predominant fatty acid
identified in the sample, followed by palmitic (C16:0) and
linoleic (C18:2n6) acids. In addition to these three fatty
acids, 19 other compounds were identified and quantified
(Figure 1(b)). The sample had a higher percentage of poly-
unsaturated fatty acids (PUFAs) (48.82%), followed by
saturated fatty acids (SFAs) (39.19%) and monounsatu-
rated fatty acids (MUFAs) (11.86%) (Figure 1(c)). The
PUFAs/SFAs and n-6/n-3 ratios assessed were 1.25 and
3.37, respectively.
3.4. Microbiological Quality and Safety. The results from the
microbiological quality and safety analysis of H. speciosa
leaves are outlined in Table 2.
3.5. Antihemolytic Activity. Figure 2 shows the results of the
protective activities of the EEHS (59.59± 1.42%), rutin
(29.67± 2.11%), catechin (23.67± 1.97%), and isoquercetin
(20.97± 1.38%) against AAPH-induced hemolysis.
3.6. Antimutagenic Activity. The results from the study of the
antimutagenic potentials of the EEHS, rutin, catechin, and
isoquercetin are outlined in Table 3. In all of the EEHS
concentrations tested (5–15μg/mL), a high antimutagenic
activity was observed in the Salmonella typhimurium
TA98 and TA100 strains exposed to different mutagens
with (S9+) and without (S9−) metabolic activation. Among
the flavonoids, rutin (0.1–0.25μg/mL) showed moderate
antimutagenic activity in the Salmonella typhimurium
TA98 strain without metabolic activation.
3.7. Enzyme-Inhibiting Activity
3.7.1. Cholinesterase-Inhibiting Activity. Table 4 shows that
the EEHS had higher AChE-inhibiting activity than isoquer-
cetin (2.0 times), rutin (1.7 times), and catechin (1.5 times)
and lower activity than eserine (reference AChE inhibitor).
The EEHS showed higher BChE-inhibiting activity than
isoquercetin (1.8 times), catechin (1.6 times), and rutin (1.4
times) and lower activity than eserine (reference BChE
inhibitor) (Table 4).
3.7.2. Tyrosinase-Inhibiting Activity. The EEHS showed
4.3-, 3.8-, and 3.7-fold higher tyrosinase-inhibiting activity
than catechin, isoquercetin, and rutin, respectively (Table 4).
The tyrosinase-inhibiting activities of all compounds were
lower than that of the reference inhibitor kojic acid
(Table 4).
3.7.3. Hyaluronidase-Inhibiting Activity. The EEHS showed
1.8-fold higher hyaluronidase-inhibiting activity than rutin
and catechin and 2.6-fold higher activity than isoquercetin
(Table 4). However, the hyaluronidase-inhibiting activities
of the EEHS and flavonoids were lower than that of the
reference compound, epigallocatechin (EGC) (Table 4).
3.7.4. Pancreatic Lipase-Inhibiting Activity. Table 4 shows
that the EEHS had higher pancreatic lipase-inhibiting
activity than isoquercetin (8.1 times), catechin (7.4 times),
and rutin (5.2 times) and lower activity than that of orlistat
(reference inhibitor of pancreatic lipase).
3.7.5. α-Amylase- and α-Glucosidase-Inhibiting Activities.
Table 4 shows that the EEHS had higher α-amylase-
Table 1: Physicochemical characterization of Hancornia speciosa
leaf samples.
Physicochemical characterization Results/100 g
Ash 2.2± 0.0123 g
Protein 14.7± 0.1811 g
Lipid 0.14± 0.0006 g
Sugars 82.9± 0.0174 g
Energy 392.0± 0.049 kcal
Values are expressed as the mean ± SEM of experiments performed in
triplicate.
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inhibiting activity than rutin (2.2 times), isoquercetin (2.0
times), catechin (1.4 times) and the reference inhibitor acar-
bose (1.9 times). The assessment of the α-amylase-inhibiting
activity of flavonoids in comparison with the reference
compound acarbose showed that catechin had a higher
activity than acarbose (Table 4). The EEHS showed higher
α-glucosidase-inhibiting activity than rutin (2.4 times),
catechin (2.2 times), isoquercetin (1.7 times), and acarbose
(1.6 times) (Table 4).
3.8. In Vivo Studies
3.8.1. Oral Glucose Tolerance Test in Normoglycemic Wistar
Rats. Figure 3 shows that the normoglycemic rats challenged
with glucose overload show significantly decreased blood
glucose levels when treated with the EEHS (200mg/kg).
3.8.2. Glycemic Assessment in Diabetic Wistar Rats. In













































































































































Figure 1: (a) Chromatographic fatty acid profile of Hancornia speciosa leaf samples. (b) Chemical composition of fatty acid methyl esters
(FAMEs): caprylic acid (C8:0), capric acid (C10:0), lauric acid (C12:0), tridecanooic acid (C13:0), myristic acid (C14:0), myristoleic acid
(C14:1), pentadecanoic (C15:0), palmitic acid (C16:0), palmitoleic acid (C16:1), heptadecanoic acid (C17:0), cis-10-heptadecanoic acid
(C17:1), stearic acid (C18:0), oleic acid (C18:1n9c+t), linoleic acid (C18:2n6c), α-linolenic acid (C18:3n3), arachidic acid (C20:0), cis-11-
eicosenoic acid (C20:1), cis-11,14-eicosadienoic acid (C20:2), heneicosanoic acid (C21:0), behenic acid (C22:0), tricosanoic acid (C23:0),
and nervonic acid (C24:1). (c) Total composition of saturated fatty acids (SFAs), monounsaturated fatty acids (MUFAs), and
polyunsaturated fatty acids (PUFAs) of Hancornia speciosa leaf samples. Values are expressed as the mean± SEM of three independent
experiments performed in duplicate. †P < 0 05 compared with the SFA group versus the PUFA group; ###P < 0 001 compared with the
MUFA group versus the PUFA and SFA groups; and ∗∗∗P < 0 001 compared with the PUFA group versus the MUFA groups.
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400mg/dL and without glucose overload, no decreases
in the blood glucose levels were observed after acute
(Figure 4(a)) and chronic (Figure 4(b)) treatments with the
EEHS (200mg/kg). Only the experimental group metformin
(MET, 120mg/kg) showed decreased blood glucose levels
(Figures 4(a) and 4(b)).
4. Discussion
Brazil has different biomes with high biological diversity and
native species, which are often used as medicinal plants.
Studying the pharmacological properties of these plants used
in traditional medicine ensures its scientific record and
strengthens the traditional knowledge accumulated over
centuries. Among these plants, H. speciosa has been
described as a highly versatile species. This plant is tradition-
ally used to treat various diseases and has a high economic
and biotechnological potential for drug development because
its leaves and other parts are sold as tea [4, 39].
Despite the proven therapeutic effect, the increase in the
consumption of natural products has become a public health
problem because low-quality products without validation of
raw material safety and efficiency may be purchased [3].
Natural products may contain a large number of fungi and
bacteria; these microorganisms are usually from the soil,
which is the natural microbiota or even introduced during
inappropriate handling of harvest, drying, and storage of
these products (WHO, 2007). In this sense, several studies
have been carried out with the purpose of assuring the quality
and microbiological safety of medicinal plants [40–42].
Although the European Community legislation does not have
defined microbiological standards for aromatic dry plants,
the World Health Organization (WHO), the European Spice
Association (ESA), and the Codex Code of Hygienic Practice
specify that aromatic dry plants need to have acceptable
microbial contamination levels and absence of pathogenic
microorganisms, such as Salmonella sp. and Clostridium sp.
[2, 43, 44]. Thus, this study aimed to ensure that the raw
material used is of high quality and safe for consumption by
testing the microbiological quality and safety of H. speciosa
leaves, which are in accordance with current standards
established by the World Health Organization for products
intended for human consumption [2].
After the initial quality and safety assessment as well as
physicochemical analysis, including the quantification of
the total lipids extracted from H. speciosa leaves, different
fatty acids were identified. Among the fatty acids, α-linolenic
acid (polyunsaturated omega-3), considered an essential fatty
acid only obtained from the diet [45], was the predominant
fatty acid found in H. speciosa leaves, followed by palmitic
(saturated) and linoleic (polyunsaturated omega-6) acids.
Moreover, the PUFAs/SFAs and n-6/n-3 fatty acid ratios cal-
culated indicate good nutritional quality, including health
benefits [46]. α-Linolenic acid cannot be synthesized by
humans; however, dietary α-linolenic acid is the precursor
of eicosapentaenoic and docosahexaenoic acids, which are
anti-inflammatory eicosanoids [47, 48].
Furthermore, the quantification of natural antioxidants,
including lipophilic antioxidants as well as the total phenols
and flavonoids in natural products, provides key parameters
to assess the quality and biological potential of herbal prod-
ucts [49]. In this study, the lipophilic antioxidants chloro-
phyll a and b, β-carotene, and lycopene were identified and
quantified in H. speciosa leaves. The main carotenoids
include the hydrocarbons β-carotene and lycopene [50].
The great interest in these nutrients results from their biolog-
ical and physiological functions [51]. Some carotenoids, in
addition to vitamin A (retinol) precursors, have antioxidant
properties and improve the immune response [52]. More-
over, a previous study by Santos et al. [4] with the EEHS
reported higher concentrations of total phenols than those
described for H. speciosa fruit extracts [53].
Phenolic compounds are hydrogen donors capable of
directly removing free radicals and reducing oxidative dam-
age [4, 54, 55]. Extracts from medicinal plants with phenols
and flavonoids, including H. speciosa, are described for their
ability to activate endogenous antioxidant systems and to
inhibit lipid peroxidation in human erythrocytes [4, 56, 57].
Accordingly, the flavonoids rutin, catechin, and isoquercetin,
previously identified by Santos et al. [4] in the EEHS, showed
antioxidant activity in this study, which was confirmed by the
protection against human erythrocyte hemolysis resulting
from lipid peroxidation. However, the results showed a pos-
sible synergistic effect between components of the extract
because the EEHS showed a higher antihemolytic activity
than the flavonoids alone. Peroxyl radicals promote hemoly-
sis by oxidizing lipids and proteins of the cell membrane [58].
In vitro and in vivo studies show that natural extracts and
flavonoids have antioxidant activity by inhibiting lipid
peroxidation in the erythrocytes and cardiomyocytes of rats
subjected to oxidative stress [4, 59, 60]. The protection
against lipid peroxidation promoted by the test samples
may be associated with the direct peroxyl radical scavenging
activity or with the activation of enzymatic antioxidant
mechanisms, such as glutathione, catalase, and superoxide
dismutase [56, 58].
Accordingly, endogenous intracellular antioxidant path-
ways naturally protect the human body from the frequent
contact with mutagenic agents. These structures stabilize
highly reactive species that damage deoxyribonucleic acid
(DNA) [61]. However, natural defense mechanisms may
not suffice, thus highlighting the importance of investigating
Table 2: Microbiological analysis of Hancornia speciosa leaf
samples.
Microbiological analysis Results
Aerobic mesophiles 6.25× 104 ± 0.45 cfu/g
Molds and yeast 6.82× 103 ± 0.18 cfu/g
Total coliforms 12.4× 103 ± 0.40 cfu/g
Escherichia coli <1 cfu/g
Sulphite-reducing Clostridia Absent
Salmonella spp. Absent
Staphylococcus aureus <10 cfu/g
Values are expressed as the mean ± SEM of experiments performed
in triplicate.
8 Oxidative Medicine and Cellular Longevity
exogenous antioxidant compounds with antimutagenic
activity [62].
The Ames test has been recommended to assess the
antimutagenic effects of several natural molecules, including
plant compounds. This assay can detect frameshift or mis-
sense mutations [63]. The EEHS showed antimutagenic
activity when Salmonella typhimurium TA98 and TA100
strains were exposed to the direct mutagens 4-NO, a sub-
stitution agent that primarily acts on guanine (G) residues,
inducing transitions from guanine-cytosine (GC) to
adenine-thymine (AT) [64], and SAZ, which induces
mutagenesis through the production of the DNA-
interacting metabolite L-azidoalanine, inducing transitions
from GC to AT [65]. Moreover, the EEHS showed anti-
mutagenic activity when S. typhimurium TA98 and
TA100 strains were exposed to the indirect mutagen
AFB1, a toxin that stimulates the release of free radicals,
thereby triggering chromosomal aberrations [66]. Among
the flavonoids, rutin showed moderate antimutagenic
activity when S. typhimurium TA98 strains were exposed
to 4-NO. A study using the Ames test suggests that flavo-
noids may show antimutagenic effects through different


















Figure 2: Antihemolytic activities of the ethanolic extract fromHancornia speciosa leaves (EEHS) (20 μg/mL) and the flavonoids rutin (Rut),
catechin (Cat), and isoquercetin (Isoq) (20 μg/mL) against 50mM AAPH-induced hemolysis. Values are expressed as the mean± SEM of
experiments performed in triplicate. ∗∗∗P < 0 001 when the EEHS group is compared with the rutin, catechin, and isoquercetin groups.
Table 3: Antimutagenic activities of the ethanolic extract from Hancornia speciosa leaves (EEHS), rutin (Rut), catechin (Cat), and
isoquercetin (Isoq) in Salmonella typhimurium TA98 and TA100 strains.













NC 39.0 ± 3.2 — 50.3± 3.8 — 63.3 ± 2.6 — 46.7± 2.4 —
4-NO 3 198.6± 4.6 0 — — — — — —
SAZ 3 — — — — 256.7± 2.9 0 — —
AFB1 3 — — 231.0± 6.6 0 — — 236.3± 5.9 0
EEHS
5 35.0± 2.1∗∗∗ 82.3± 0.6 18.6 ± 0.9∗∗∗ 92.3 ± 0.3 95.0± 2.9∗∗∗ 63.0 ± 1.0 75.0± 2.9∗∗∗ 68.0± 1.5
10 11.3± 2.3∗∗∗ 94.0± 1.7 8.0± 1.1∗∗∗ 96.7 ± 0.3 70.7± 2.3∗∗∗ 72.3 ± 0.9 57.3± 4.3∗∗∗ 75.7± 1.4
15 7.7± 1.20∗∗∗ 96.0± 0.6 5.6± 0.3∗∗∗ 97.6 ± 0.3 44.0± 3.8∗∗∗ 82.7 ± 1.2 36.0± 3.6∗∗∗ 84.7± 1.3
Rut
0.1 136.0± 5.5∗∗∗ 31.3± 4.1 231.3± 4.1 −0.04 ± 0.01 269.7± 4.7 −0.05 ± 0.01 254.7± 5.2 0.01 ± 0.01
0.25 148.3± 0.9∗∗∗ 25.3± 1.2 248.6± 2.0 −0.07 ± 0.01 285.7± 2.9 −0.11 ± 0.04 269.3± 0.6 −0.05± 0.01
0.5 175.0± 2.9 12.3± 0.6 >300 — 285.7± 0.9 −0.39± 0.5 275.3± 2.9 0.07 ± 0.01
Cat
0.1 211.0± 6.08 −0.06± 0.01 240.0± 7.1 −0.04 ± 0.01 284.7± 1.4 −0.11 ± 0.03 285.0± 3.6 −0.11± 0.01
0.25 240.0± 7.63 −20.6 ± 2.2 272.3± 3.6 −18.0 ± 3.5 289.3± 2.2 −0.12 ± 0.02 280.3± 4.8 −0.09± 0.01
0.5 >300 — >300 — 291.0± 5.5 −0.06± 0.1 284.7± 6.8 −0.11± 0.02
Isoq
0.1 195.6± 5.0 0.01± 0.01 201.0± 4.3 0.1± 0.01 273.3± 3.3 −0.06 ± 0.01 281.0± 7.4 0.05 ± 0.06
0.25 >300 — 245.3± 6.6 −0.06 ± 0.01 284.3± 2.2 −0.31 ± 0.33 279.3± 5.8 −0.09± 0.02
0.5 >300 — >300 — 289.0± 2.8 −0.12 ± 0.04 282.3± 4.3 −0.37± 0.03
Salmonella typhimurium TA98 and TA100 strains (CFUs) exposed to the direct mutagens 4-nitroquinoline-1-oxide (4-NO) and sodium azide (SAZ) without
metabolic activation (S9−). Salmonella typhimurium TA98 and TA100 (CFUs) strains exposed to the indirect mutagen aflatoxin B1 (AFB1) with metabolic
activation (S9+, microsomal activation system: microsomal fraction of rat liver homogenate). Values are expressed as the mean ± SEM of the experiment
performed in triplicate. ∗∗∗P < 0 001 when the means of the treated groups are compared with the 4-NO (TA98/without S9), SAZ (TA100/without S9), and
AFB1 (TA98 and TA100 with S9) groups. —: unvalued.
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mechanisms, including scavenging bacterial mutagens,
interacting with mutagenic reactive intermediates and
affecting microsomal enzymes [67]. However, flavonoids
may also show dual concentration-dependent effects, either
mutagenic or antimutagenic [68]. Thus, the antimutagenic
activity of the extract and rutin could be related to the
antioxidant activity because other studies have reported
that antioxidant compounds are related to the antimuta-
genic activity [69, 70].
The ability of flavonoids to reduce oxidative stress is also
related to the decreased risk associated with neurodegenera-
tive diseases [71]. In this context, medicinal plants and phe-
nolic derivatives have been recognized for their inhibitory
activities against enzymes involved in neurodegenerative
diseases [70–72]. Alzheimer’s disease is a degenerative and
progressive disease and is the form of dementia most
commonly found among elderly people [73]. This disease is
characterized by the presence of β-amyloid plaques with
neurofibrillary complications and the degeneration or atro-
phy of cholinergic neurons [74, 75]. The loss of cholinergic
neurons results in the reduced availability of the cholinergic
neurotransmitter acetylcholine, leading to impaired cogni-
tion in Alzheimer’s disease [76]. However, the level of this
neurotransmitter can be increased in the brain by inhibiting
the activity of cholinesterases, enzymes that break down ace-
tylcholine [77]. In this context, AChE and BChE inhibitors
are used to increase the synaptic levels of acetylcholine,
which is considered the main disease treatment approach
[78]. The increase in acetylcholine levels improves the
communication between nerve cells that use it as the only
neurotransmitter [79]. Other in vitro studies using the
flavonoids rutin and quercetin reported findings on the
AChE- and BChE-inhibiting activities [72, 80]. In vivo
phenolic and flavonoid derivatives, such as rutin and querce-
tin, also show AChE- and BChE-inhibiting activities and
improve the cognitive abilities of animals, including those
subjected to neurotoxicity [81, 82]. Furthermore, a molecular
coupling study has shown the hydrophobic interactions and
strong hydrogen bonds between quercetin and the enzymes
AChE and BChE, thus proposing this mechanism as the basis
for the enzyme-inhibiting activity [83].
The activity of tyrosinase, another enzyme related to
neurodegenerative diseases, was inhibited by the H. speciosa
extract and flavonoids. Tyrosinase is a polyphenol oxidase
enzyme involved in the synthesis of melanin (skin and hair)
and neuromelanin [84], and it is considered a key target in
the search for new drugs against Parkinson’s disease [72].
This neurodegenerative disease results from the deficiency
of dopaminergic neurons [84]. Studies suggest that tyrosi-
nase plays a role in the formation of reactive species that
oxidize dopamine, which triggers the production of more
reactive oxygen species leading to neuronal death [85, 86].
Furthermore, the increase in lipid peroxidation in the
brains of patients with Parkinson’s disease has been
reported [87, 88].
Table 4: Acetylcholinesterase- (AChE-), butyrylcholinesterase- (BChE-), tyrosinase-, hyaluronidase-, pancreatic lipase-, α-amylase-, and
α-glucosidase-inhibiting activities of the ethanolic extract from Hancornia speciosa leaves (EEHS), rutin (Rut), catechin (Cat), and
isoquercetin (Isoq).
AChE BchE Tyrosinase Hyaluronidase Pancreatic lipase α-Amylase α-Glucosidase
IC50 (μg/mL) IC50 (μg/mL) IC50 (μg/mL) % (μg/mL) IC50 (μg/mL) IC50 (μg/mL) IC50 (μg/mL)
EEHS 257.2± 10.8∗∗∗ 190.3± 9.8∗∗∗ 159.4± 2.4∗∗∗ 22.5± 1.6∗∗∗ 3.3± 0.3∗∗∗ 35.8± 2.9∗∗∗ 31.6± 1.5∗∗∗
Rut 437.6± 9.9 272.9± 8.8 583.2± 12.9 12.3± 0.9 17.2± 0.9 77.9± 0.6 74.9± 2.3
Cat 379.0± 8.4 312.6± 6.7 679.2± 11.8 12.3± 0.8 24.5± 0.6 50.3± 2.6∗∗ 68.4± 1.6
Isoq 527.8± 12.1 342.8± 7.6 610.7± 7.1 8.8± 0.8 26.7± 1.6 73.2± 1.5 54.9± 2.3
Eserine 0.005± 0.001 0.037± 0.003 — — — — —
Kojic ac. — — 6.5± 0.5 — — — —
EGC — — — 97.9± 0.8 — — —
Orlistat — — — — 0.016± 0.02 — —
Acarbose — — — — — 67.5± 1.5 49.7± 2.1
Values are expressed as the mean (μg/mL), IC50, and percentage ± SEM of experiments performed in triplicate. ∗∗∗P < 0 001 when comparing the treatment
groups with the acarbose control groups, epigallocatechin (EGC). ∗∗P < 0 01 compared with the catechin group versus the rutin, isoquercetin, and control
groups (acarbose). ∗∗∗P < 0 001 compared with the EEHS group versus the rutin, catechin, isoquercetin, and control groups (eserine, kojic acid, ECG:
epigallocatechin, orlistat, or acarbose).






















Figure 3: Oral glucose tolerance test in normoglycemic Wistar rats
subjected to treatment with the control and ethanolic extract of
Hancornia speciosa leaves (EEHS) at 200 and 400mg/kg. Times
assessed: 0, 30, 60, 120, and 180min. Values are expressed as the
mean± SEM, n = 5. ∗∗P < 0 01 and ∗P < 0 05 when comparing
treatment groups with the control group.
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In addition to those activities, tyrosinase also plays an
enzymatic role in fruit and vegetable browning and skin
hyperpigmentation [89]. Accordingly, tyrosinase inhibitors
are mainly used as chemical agents to reduce food browning
and human skin hyperpigmentation [90, 91]. Although
melanogenesis is mainly responsible for skin coloration and
the protection of skin against sun-related lesions, abnormal
skin hyperpigmentation causes serious esthetic problems
[92]. Kojic acid, a chemical product commonly used for skin
whitening, has health adverse effects, including cytotoxic and
mutagenic effects [93]. Therefore, compounds derived from
natural products have become the alternative to those
products, including flavonoids, which have stood out as
inhibitors of this enzyme. Flavonoids are used to suppress
melanogenesis in dermatological diseases associated with
skin hyperpigmentation [94]. The assessment of tyrosinase
inhibition by the EEHS and flavonoids observed in this study
may be related to direct interaction with tyrosinase because
flavonoids, including the derivative quercetin, interact with
the enzyme forming a flavonoid-copper-enzyme complex,
according to Kim et al. [90].
In addition to neurodegenerative diseases and skin hyper-
pigmentation, inflammatory processes are also involved in
the origin of other diseases [75].
In this context, H. speciosa has been used in traditional
medicine to treat inflammatory diseases [95]. In vitro and
in vivo studies with extracts from the plant and flavonoids
isolated from its extracts have shown anti-inflammatory
















































Figure 4: Glycemic curve without glucose overload in diabetic Wistar rats subjected to acute (a) and chronic (b) treatments with the control,
EEHS (200mg/kg) and metformin (MET, 120mg/kg). Times tested: 0, 30, 60, 120, and 180min. Values are expressed as the mean± SEM,
n = 5. ∗∗P < 0 01 and ∗P < 0 05 when comparing treatment groups with the control group.
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activity through various mechanisms, including the
inhibition of the enzymes nitric oxide synthase (iNOS)
and cyclooxygenase-2 (COX-2), the proinflammatory
transcriptional factor NF-κB, and the inflammatory cyto-
kines interleukin 6 (IL-6) and tumor necrosis factor alpha
(TNF-α) [5, 6, 96–98].
Many commercially available anti-inflammatory drugs
have harmful side effects. Therefore, the search for new ther-
apies is extremely important [98]. Hyaluronidase-inhibiting
compounds may be used as anti-inflammatory drugs [99].
The hyaluronidase enzymatic activity not only promotes
chemokine and cytokine induction but may also degrade
hyaluronic acid [99, 100]. Studies show that the high-
molecular-weight hyaluronic acid has an anti-inflammatory
activity, whereas its low-molecular-weight degradation
products are potent proinflammatory molecules [101].
Hyaluronic acid is the main component of the extracellular
matrix and is considered one of the main molecules involved
in the tissue regeneration process. The activity of hyaluronic
acid and its degradation products have been related to
inflammation, cell migration, and angiogenesis through
modulation of specific receptors [102]. Some of the conse-
quences of hyaluronic acid degradation resulting from the
activity of the enzyme hyaluronidase are bone loss, inflam-
mation, and pain [103].
Another diseased related to inflammation is obesity
[104]. Obesity is defined as excess weight [105]. Some of
the drug alternatives to treat obesity are related to the inhibi-
tion of enzymes involved in fat digestion and absorption
[106]. Dietary fat digestion is necessary for its absorption,
and such a process occurs through lipid hydrolysis resulting
from lipase activity, thereby releasing fatty acids and glycerol
[107]. The inhibition of pancreatic lipase, the main enzyme
responsible for triglyceride digestion, is a strategy to reduce
fat absorption and control weight that may decrease obesity
[19]. In this context, many medicinal plants and phenolic
derivatives have lipase-inhibiting activity [16–19]. H. spe-
ciosa is commonly used to treat obesity [108], and in this
study, the EEHS showed higher lipase-inhibiting activity in
the pancreas than flavonoids and a lower activity to orlistat,
a potent commercial inhibitor of this enzyme. These results
suggest that the EEHS and the flavonoids tested in this study
promote interaction with the lipase enzyme because, as
reported by a study, flavonoids, including rutin and quercetin
derivatives, interact with lipase forming a flavonoid-enzyme
complex, primarily through hydrophobic and hydrophilic
bonds, thereby decreasing or inhibiting the activity of the
enzyme [109].
Furthermore, obese patients have a high risk of develop-
ing diseases, including type 2 diabetes, the most prevalent
form of the disease [105, 110]. Type 2 diabetes mellitus is a
complex metabolic disease characterized by hyperglycemia
resulting from increased insulin resistance [111, 112].
Decreasing postprandial hyperglycemia in patients with
type 2 diabetes has been considered the most common
therapeutic approach for disease control. Furthermore, this
treatment reduces the risk of developing comorbidities and
complications, including oxidative stress, obesity, and
cardiovascular diseases [113]. This decrease may be achieved
by inhibiting the enzymes involved in dietary glucose release,
including the enzymes α-amylase and α-glucosidase [107].
Pancreatic α-amylase breaks down starch molecules [114],
and intestinal α-glucosidase catalyzes the final step of the
digestion of starch and disaccharides into glucose for absorp-
tion [115]. Therefore, α-amylase and α-glucosidase inhibitors
decrease the postprandial blood glucose levels of diabetic
patients [116].
Accordingly, the EEHS, rutin, catechin, and isoquercetin
inhibit the enzyme α-amylase, and the enzyme-inhibiting
activities of the EEHS and catechin are higher than that of
the commercial drug acarbose. The EEHS, rutin, catechin,
and isoquercetin also showed α-glucosidase-inhibiting
activity, although only the EEHS-induced α-glucosidase-
inhibiting activity was higher than that of acarbose. Thus,
these results demonstrate the high antidiabetic potential of
the extracts and flavonoids tested because they had higher
inhibitory activities than the commercial drug sold to treat
diabetes. In addition, previous studies with ethanolic leaf
extracts from H. speciosa and the flavonoid rutin, the main
compound present in the EEHS that was tested in this study,
have reported α-glucosidase-inhibiting activity as well as
in vitro and in vivo control of the blood glucose levels [11].
Thus, the EEHS-induced α-amylase and α-glucosidase
inhibition is a possible mechanism for the reduction of blood
glucose levels by the EEHS in animals subjected to glucose
overload because diabetic animals showed no improvement
in the insulin sensitivity of these animals when compared
with treatment with the insulin sensitizer metformin. There-
fore, the in vitro and in vivo findings of this study confirm the
role of the EEHS in controlling postprandial hyperglycemia.
Taken together, the results ensure the microbiological
quality and safety of H. speciosa leaves, and carotenoids
and polyunsaturated fatty acids in the leaves were also iden-
tified. In addition, the antioxidant, antimutagenic, anti-
inflammatory, anti-Alzheimer’s disease, anti-Parkinson’s
disease, antiobesity, and antihyperglycemic activities of the
EEHS were identified.
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